Drugs / BI 54903 XX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02221375 | Jun → Sep 2008 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT02222428 Comparator | Apr → Jul 2009 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02220660 Comparator | Mar → Jun 2009 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 54903 XX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02221375 ↗ |
| Route | Inhaled | “following inhalation of the free dose combination of BI 1744 CL (as aqueous solution for inhalation, AIS) and BI 54903 XX (EIS), respectively” NCT02220660 ↗ |